Effects of HBsAg carriers on pregnancy complications in pregnant women: a retrospective cohort study

Global and regional incidence of intrahepatic cholestasis of pregnancy: a systematic review and meta-analysis

BACKGROUND

Intrahepatic cholestasis of pregnancy (ICP) can be a source of significant distress for both pregnant women and the fetus, impairing the quality of life and well-being of pregnant women, leading to psychological disorders among pregnant women with severe or recurrent ICP, and causing life-threatening complications among fetuses. Regrettably, our current understanding of ICP globally is limited, lacking a comprehensive estimation of its incidence. Therefore, in this systematic review and meta-analysis, we aimed to investigate the global and regional incidence of ICP and identify factors that account for its variety across studies.

METHODS

A comprehensive search strategy was implemented across PubMed, Scopus, and Web of Science databases. To stabilize the variance, the Freeman-Tukey double arcsine transformation was employed. Subgroup analyses were conducted based on continent, publication type, study design and timing, regional classifications, developmental status, and World Bank income grouping. A multivariate meta-regression analysis was performed to estimate the effects of the continuous moderators on the effect size.

RESULTS

A total of 42,972,872 pregnant women were analyzed from 302 studies. The overall pooled incidence [95% confidence interval] of ICP was 2.9% [2.5, 3.3]. Studies with larger sample sizes tended to provide significantly lower estimates of ICP incidence: 1.6% [1.3, 2] vs 4.7% [3.9, 5.5]. Asia had the highest incidence of ICP among the continents, whereas Oceania had the lowest. Countries that were classified as developed and with higher income had a lower incidence of ICP than those classified as developing and low and middle income.

CONCLUSIONS

The findings of this study will provide valuable insights into the current knowledge regarding the association of the quality of public health and socioeconomic variations with the incidence of ICP on a global scale.

Positive association between chronic hepatitis B virus infection and anemia in pregnancy in Southern China

This observational investigation aimed to explore potential risk factors for anemia in pregnancy. Firstly, a cross-sectional study was conducted, encompassing a review of clinical data of 43,201 pregnant women admitted to the Hainan Women and Children's Medical Center between January 2017 and December 2020. Comparison between women with and without anemia in pregnancy revealed significant differences between the two groups concerning age, gestational diabetes, hypothyroidism, hyperthyroidism, chronic hepatitis B virus infection, syphilis infection, and human immunodeficiency virus infection. Multivariable logistic regression analysis showed that chronic hepatitis B virus infection was significantly associated with anemia during pregnancy (AOR   2.97, 95% CI 2.57-3.44, p < 0.0001). Subsequently, a retrospective cohort comprising 86 cases with chronic hepatitis B virus infection and 129 control subjects recruited from the Hainan Women and Children's Medical Center from November 2021 and January 2023 was examined. Results of the examination revealed a corroborative association between chronic hepatitis B virus infection and anemia in pregnancy (OR  2.13, 95% CI 1.20-3.79, p = 0.0092), particularly manifesting in the third trimester of gestation. Further analysis unveiled distinctive hematological alterations among cases with chronic hepatitis B virus infection, characterized by diminished erythrocyte size and reduced levels of corpuscular hemoglobin. Collectively, these findings underscore a positive association of chronic hepatitis B virus infection with anemia during pregnancy.

Chorionic-based intrahepatic cholestasis in pregnancy on perinatal outcome in twin pregnancies

This study investigates the impact of twin intrahepatic cholestasis in pregnancy (ICP) in different chorionicity scenarios on pregnancy outcome and risk factors. This retrospective study was designed to investigate the association between ICP and pregnancy outcomes and associated risk factors. Logistic regression analysis was used to verify the correlation between ICP and pregnancy outcome and the associated risk factors with the risk of ICP. Pregnant women with ICP had less gestational weight gain (16.19 ± 5.28 vs 17.78 ± 7.19, P = .018), a smaller number of deliveries (16.26% vs 26.40%, P = .016), and less spontaneous pregnancy (50.41% vs 61.73%, P = .019). The mean birth weight of pregnant women without ICP was lower (2328.07 ± 461.82 vs 2404.70 ± 504.58, P = .023), and the prepregnancy hepatitis B virus (HBV) antigen carrying rate was lower (12.20% vs 6.16%, P = .021). Pregnancy weight gain (0.95 (0.92, 0.99) P = .009) and the number of weeks in labor (0.88 (0.81, 0.96) P = .003) were negatively associated with the risk of ICP. Assisted reproductive technology use (1.38 (0.70, 1.79) P = .635) and HBV carrier before pregnancy (2.51 (1.42, 4.48) P = .002) were positively associated with ICP risk. In monochorionic twins, those with ICP were more likely to have abnormal amniotic fluid (15.79% vs 2.16%, P = .012), while those without ICP were less likely to have abnormal amniotic fluid (0.90 (0.83, 0.97) P = .004). In double chorion twins, the incidence of preterm birth was higher in women with ICP (40.00% vs 24.14, P = .002), and the risk of preterm birth was reduced in women without ICP (0.87 (0.79, 0.96) P = .005). In terms of neonatal outcomes, women with ICP were more likely to have a stillbirth (5.26% vs 0.48% P = .037), and stillbirth was less likely to occur without ICP (0.95 (0.92, 0.98) P = .002). Our study illustrates that twin pregnancies with maternal comorbid ICP have lower birth weight, degree of weight gain during pregnancy and prepregnancy HBV carriage is strongly associated with the development of ICP. ICP contributes to adverse perinatal outcomes such as stillbirth, preterm labor, and differentiates between different chorionic twin pregnancy outcomes. The risk of ICP is differently affected by the degree of weight gain during pregnancy, gestational week of delivery, assisted reproductive technology, and prepregnancy HBV carriage.

ICP - could there be a virus in the works?

Intrahepatic cholestasis of pregnancy (ICP) is the most common liver-specific disorder affecting pregnant women, with an Australian incidence of 0.6% pa and recurring in 70% of those affected. ICP causes mild to severe pruritus, often resulting in considerable skin excoriations, profound sleep disturbances, and severe anxiety, and yet the aetiology and optimal treatment or management of this condition remains unknown. In this review, we consider the role of viruses in causing or exacerbating ICP and discuss viruses that have been most closely implicated in the disease, including the role of Hepatitis B and Hepatitis C viruses in ICP.

Hepatitis B virus infection during pregnancy and the risk of postpartum hemorrhage: a protocol for systematic review and meta-analysis

Background

Hepatitis B virus (HBV) infection is a significant public health issue worldwide, with a hepatitis B surface antigen (HBsAg) seroprevalence of 3.5%. Maternal HBV infection during pregnancy, a common comorbidity, is associated with an increase in the risk of adverse obstetric and perinatal outcomes. However, the relationship between maternal HBV infection and postpartum hemorrhage (PPH), a leading contributor to maternal morbidity and mortality, is currently uncertain. The aim of this study is to comprehensively clarify the potential impact of maternal HBV on PPH risk.

Methods and Analysis

The authors initially searched five English databases and three Chinese databases from their inception to 26th June 2023. Two reviewers will independently conduct study selection, data extraction, and quality assessment. Cohort and case-control studies investigating the effect of maternal HBV infection on PPH will be included, with study quality assessed using the Newcastle-Ottawa Scale (NOS). Meta-analyses will be performed using a fixed-effects model for I 2≤50% or a random-effects model otherwise. Several categories of subgroup analyses (e.g. sample size more than 1000 vs. less than 1000) and sensitivity analyses (e.g. omit NOS scores less than 7) will be conducted, and publication bias will be assessed through funnel plots, Begg's and Egger's tests using STATA 18.0.

Ethics and Dissemination

This systematic review and meta-analysis do not require ethics approval and the results will be published in peer-reviewed journals. The findings of this systematic review will provide evidence on the impact of maternal HBV infection on PPH, which will contribute to better prevention and management of PPH in clinical practice and a better understanding of the disease burden of HBV infection.

PROSPERO registration number

CRD42023442626.

The effect of intrahepatic cholestasis in pregnancy combined with different stages of hepatitis B virus infection on pregnancy outcomes: a retrospective study

BACKGROUND AND AIMS

To investigate the impact of intrahepatic cholestasis of pregnancy (ICP) with hepatitis B virus (HBV) infection on pregnancy outcomes.

METHODS

We selected 512 pregnant women, collected the data including maternal demographics, main adverse pregnancy outcomes and maternal HBV infected markers HBeAg and HBV-DNA loads status, then have a comparative analysis.

RESULTS

There were 319 solitary ICP patients without HBV infection (Group I) and 193 ICP patients with HBV infection. Of the latter, there were 118 cases with abnormal liver function(Group II) and 80 cases with normal liver function(Group III). All HBV-infected pregnant women with ICP were divided into hepatitis Be antigen (HBeAg)-positive group (102 cases) and HBeAg-negative group (91 cases), according to the level of the serum HBeAg status; and into high viral load group (92 cases), moderate viral load group (46 cases) and low viral load group (55 cases) according to the maternal HBV-DNA level. Group II had a higher level of serum total bile acids, transaminase, bilirubin as well as a higher percentage of premature delivery, neonatal intensive care unit (NICU) admission and meconium-stained amniotic fluid (MSAF) compared with the other two groups(P < 0.05), but there were no significant differences in the above indicators between the Group I and Group III. Among the HBV-infected patients with ICP, HBeAg-positive group had a higher level of serum transaminase, bilirubin and bile acid as well as earlier gestational weeks of delivery, lower birth weight of new-borns and a higher rate of NICU admission than HBeAg-negative group (P < 0.05). Those with a high viral load (HBV-DNA > 106 IU/ml) had a higher level of transaminase, bilirubin, and bile acid as well as shorter gestational weeks of delivery, lower birth weight of new-borns and a higher rate of NICU admission compared with those with a low or moderate viral load (P < 0.05).

CONCLUSION

HBV-infected pregnant women with ICP combined with abnormal liver function have more severe liver damage, a higher percentage of preterm birth and NICU admission. HBeAg-positive status and a high HBV-DNA load will increase the severity of conditions in HBV-infected pregnant women with ICP. HBV-infected patients with ICP who have abnormal liver function, HBeAg-positive or a high viral load should be treated more actively.